Tricida, Inc., is a pre-clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics. Tricida's lead program is TRC101, a chronic treatment for complications of renal disease.
Market
Renal disease therapeutics
Location
South San Francisco,
California,
USA
Coinvestors
Limulus Venture Partners, OrbiMed Advisors, Sibling Capital